Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

Now Viewing

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

1. Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:
   1. PAPMET (Tripathi A et al. JCO 2023)
   2. Phase 2 study (Nivo + Cabo): (Lee CH, et al. ASCO 2023. Abstract 4537)

Related Videos